Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2232983 | 1.00 | MAPT (0.51) | MAPTPKMSLC6A3SLC6A4SLC6A2 | |
| SCHEMBL17486622 | 0.89 | MAPT (0.54) | MAPTPKMSLC6A3SLC6A4SLC6A2 | |
| SCHEMBL17474582 | 0.89 | MAPT (0.54) | MAPTPKMSLC6A3SLC6A4SLC6A2 | |
| SCHEMBL191245 | 0.85 | SLC6A3 (0.58) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL191246 | 0.85 | SLC6A3 (0.58) | SLC6A3SLC6A4SLC6A2 | |
| Hydrochloric Acid SCHEMBL30693151 | 0.84 | SLC6A3 (0.57) | SLC6A3SLC6A4SLC6A2 | |
| Hydrochloric Acid SCHEMBL1972504 | 0.84 | SLC6A3 (0.57) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL12188593 | 0.83 | SLC6A2 (0.46) | SLC6A3SLC6A4SLC6A2KCNH2 | |
| SCHEMBL684446 | 0.83 | SLC6A2 (0.46) | SLC6A3SLC6A4SLC6A2KCNH2 | |
| SCHEMBL1714229 | 0.81 | SLC6A2 (0.47) | SLC6A3SLC6A4SLC6A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318759-B2 | Pyrrolidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2398768-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-12-28 | — | — | EP | disclosed |
| EP-2190815-B1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | disclosed |
| US-7812021-B2 | Pyrrolidine aryl-ether as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-10-12 | — | — | US | disclosed |
| WO-2010094667-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | disclosed |
| US-20100210659-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-08-19 | — | — | US | disclosed |
| EP-2190815-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-06-02 | — | — | EP | disclosed |
| US-20090054644-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2009-02-26 | — | — | US | disclosed |
| WO-2009024502-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210659-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | OPRL1, OPRK1, OPRD1 | MAPT 1116/4885PKM 522/4885SLC6A3 6/4885 |
| US-20090054644-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | OPRL1, OPRD1, OPRK1 | MAPT 2290/4885PKM 513/4885SLC6A3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.